SR One Capital Management’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

SR One Capital Management’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-272,885	Closed	-$4.03M	–	6
2023 Q3	$4.03M	Hold	272,885	–	–	2.06%	5
2023 Q2	$5.59M	Hold	272,885	–	–	2.41%	5
2023 Q1	$2.39M	Hold	272,885	–	–	0.89%	6
2022 Q4	$2.93M	Hold	272,885	–	–	1.07%	5
2022 Q3	$3.89M	Hold	272,885	–	–	1.78%	4
2022 Q2	$9.69M	Hold	272,885	–	–	4.74%	4
2022 Q1	$27.4M	Hold	272,885	–	–	14.01%	3
2021 Q4	$56.5M	Buy	+272,885	New	+$63.3M	31.92%	2

Other funds holding EFTR

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SIMG

Sonora Investment Management Group Tucson, Arizona $1.41B AUM 20.58% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

SR One Capital Management's EFTR Position: Q4 2023 in Review

SR One Capital Management sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q4 2023, closing a stake of 272,885 shares — an estimated $4.03M sold.

SR One Capital Management first reported a position in EFTR in Q4 2021 and held it in 8 quarters. The position peaked at $56.5M in Q4 2021. 25 funds tracked by Wall St. Rank hold EFTR as of Q4 2023.

SR One Capital Management reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
SR One Capital Management sold 272,885 eFFECTOR Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $4.03M.
SR One Capital Management first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
SR One Capital Management's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $56.5M in Q4 2021.
25 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q4 2023.

Based on SR One Capital Management's 13F filing for Q4 2023, filed 12 Feb 2024.